Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.62 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.62 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | CASP3 | P42574 | 4/20 | 0.58 |
| ▸ | SENP8 | Q96LD8 | 4/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 4/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 4/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.57 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4919600 | 0.90 | NPC1 (0.74) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL24104691 | 0.87 | KDM4E (0.74) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL30136366 | 0.87 | KDM4E (0.74) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL18824223 | 0.86 | DYRK1A (0.64) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL21568257 | 0.84 | KDM4E (0.61) | MEN1KMT2AKDM4ERECQLDYRK1A | |
| SCHEMBL26034882 | 0.83 | CXCR2 (0.76) | MEN1KMT2AKDM4ERECQLDYRK1A | |
| SCHEMBL21568250 | 0.83 | BLM (0.55) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL21568179 | 0.82 | KDM4E (0.53) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL21568166 | 0.82 | DYRK1A (0.53) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL17001367 | 0.82 | DYRK1A (0.74) | MEN1KMT2ANPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | claimed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | claimed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | MEN1 4843/4885KMT2A 1905/4885NPC1 148/4885 |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | MEN1 4843/4885KMT2A 1905/4885NPC1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.